Equillium, Inc. Stock price

Equities

EQ

US29446K1060

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
2.31 USD +12.14% Intraday chart for Equillium, Inc. -16.61% +219.50%
Sales 2024 * 41.7M Sales 2025 * 55M Capitalization 81.44M
Net income 2024 * -9M Net income 2025 * -63M EV / Sales 2024 * -0.36 x
Net cash position 2024 * 96.63M Net cash position 2025 * 152M EV / Sales 2025 * -1.28 x
P/E ratio 2024 *
-8.11 x
P/E ratio 2025 *
-8.25 x
Employees 44
Yield 2024 *
-
Yield 2025 *
-
Free-Float 63.58%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Equillium, Inc.

1 day+12.14%
1 week-16.61%
Current month-7.23%
1 month-11.15%
3 months+239.71%
6 months+218.18%
Current year+219.50%
More quotes
1 week
1.61
Extreme 1.61
2.90
1 month
1.61
Extreme 1.61
2.99
Current year
0.72
Extreme 0.72
3.25
1 year
0.45
Extreme 0.45
3.25
3 years
0.45
Extreme 0.45
7.75
5 years
0.45
Extreme 0.45
27.05
10 years
0.45
Extreme 0.45
27.05
More quotes
Managers TitleAgeSince
Founder 57 17-03-15
Founder 42 17-03-15
Founder 62 17-03-15
Members of the board TitleAgeSince
Director/Board Member 78 17-04-30
Director/Board Member 56 22-01-31
Director/Board Member 71 18-08-31
More insiders
Date Price Change Volume
24-03-28 2.31 +12.14% 386,043
24-03-27 2.06 0.00% 171,229
24-03-26 2.06 -15.57% 694,489
24-03-25 2.44 -13.48% 460,372
24-03-22 2.82 +1.81% 282,219

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Equillium, Inc. is a clinical-stage biotechnology company that develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical needs. Its pipeline consists of novel, first-in-class immunomodulatory assets targeting immuno-inflammatory pathways. EQ101 is a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15, which is under evaluation in a Phase II clinical study of patients with alopecia areata. EQ102 is a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21 and is under evaluation in a Phase I first-in-human clinical study that includes healthy volunteers and celiac disease patients. Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway for the modulation of effector T cells and is under evaluation in a Phase III clinical study of patients with acute graft-versus-host disease (aGVHD) and a Phase Ib clinical study of patients with lupus/lupus nephritis.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.31 USD
Average target price
6 USD
Spread / Average Target
+159.74%
Consensus
  1. Stock
  2. Equities
  3. Stock Equillium, Inc. - Nasdaq